Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iPS-NSC refers to induced pluripotent stem cell-derived neural stem cells. These are multipotent cells generated by reprogramming adult somatic cells into induced pluripotent stem cells (iPSCs), which are then differentiated into neural stem cells. iPS-NSCs possess the capacity for self-renewal and can differentiate into various neural cell types, including neurons, astrocytes, and oligodendrocytes. They are being investigated for their therapeutic potential in regenerative medicine, particularly for neurodegenerative conditions such as Parkinson's Disease, where the aim is to replace or support damaged neurons and restore neurological function. Allife Medical Science and Technology Co., Ltd. is developing an autologous iPS-NSC therapy for Parkinson's Disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iPS-NSC.